(Q38235219)

English

Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 August 2017

0 references

Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

31 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Bin Su

1

1 reference

Europe PubMed Central

31 August 2017

Hui Sheng

2

1 reference

Europe PubMed Central

31 August 2017

Manna Zhang

3

1 reference

Europe PubMed Central

31 August 2017

Le Bu

4

1 reference

Europe PubMed Central

31 August 2017

Peng Yang

5

1 reference

Europe PubMed Central

31 August 2017

Liang Li

6

1 reference

Europe PubMed Central

31 August 2017

Fei Li

7

1 reference

Europe PubMed Central

31 August 2017

Chunjun Sheng

8

1 reference

Europe PubMed Central

31 August 2017

Yuqi Han

9

1 reference

Europe PubMed Central

31 August 2017

Shen Qu

10

1 reference

Europe PubMed Central

31 August 2017

Jiying Wang

11

1 reference

Europe PubMed Central

31 August 2017

publication date

30 July 2014

1 reference

Europe PubMed Central

31 August 2017

1 reference

Europe PubMed Central

31 August 2017

48

1 reference

Europe PubMed Central

31 August 2017

1

1 reference

Europe PubMed Central

31 August 2017

107-115

1 reference

Europe PubMed Central

31 August 2017

https://scigraph.springernature.com/pub.10.1007/s12020-014-0361-4

0 references

Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Bone, sweet bone--osteoporotic fractures in diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Osteoporosis in patients with diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Use of thiazolidinediones and fracture risk

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Operating characteristics of a rank correlation test for publication bias

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinic

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noni

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Weight loss from maximum body weight among middle-aged and older white women and the risk of hip fracture: the NHANES I epidemiologic follow-up study

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Antidiabetic therapy effects on bone metabolism and fracture risk

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0361-4

21 January 2018

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extra-pancreatic effects of incretin-based therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of incretin-based therapy in patients with heart failure and myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12020-014-0361-4

1 reference

Europe PubMed Central

31 August 2017

1 reference

Europe PubMed Central

31 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38235219&oldid=1748798926"